SPIA
FATE icon

Steward Partners Investment Advisory’s Fate Therapeutics FATE Stock Holding History

Steward Partners Investment Advisory’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-185
Closed -$1.05K – 3340
2023
Q1 		$1.05K Buy
+185
New +$1.12K ﹤0.01% 3115
2022
Q4 		– Sell
-185
Closed -$4K – 3397
2022
Q3 		$4K Hold
185
– – ﹤0.01% 2844
2022
Q2 		$5K Sell
185
-90
-33% -$2.48K ﹤0.01% 2764
2022
Q1 		$11K Buy
275
+160
+139% +$6.2K ﹤0.01% 2611
2021
Q4 		$7K Buy
115
+25
+28% +$1.42K ﹤0.01% 2721
2021
Q3 		$5K Buy
+90
New +$7.06K ﹤0.01% 2800

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Steward Partners Investment Advisory's FATE Position: Q2 2023 in Review

Steward Partners Investment Advisory sold out of Fate Therapeutics (FATE) in Q2 2023, closing a stake of 185 shares — an estimated $1.05K sold.

Steward Partners Investment Advisory first reported a position in FATE in Q3 2021 and held it in 6 quarters. The position peaked at $11K in Q1 2022. 188 funds tracked by Wall St. Rank hold FATE as of Q2 2023.

  • Steward Partners Investment Advisory reported no remaining Fate Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 185 Fate Therapeutics shares in Q2 2023, an estimated $1.05K.
  • Steward Partners Investment Advisory first reported a position in Fate Therapeutics in Q3 2021 and held it in 6 quarters.
  • Steward Partners Investment Advisory's Fate Therapeutics position peaked at $11K in Q1 2022.
  • 188 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2023.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2023, filed 14 Aug 2023.